Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0EC2K
|
||||
| Former ID |
DNC009423
|
||||
| Drug Name |
SIPATRIGINE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10:I21, I22, R52, R52.1-R52.2, R60.9, G89] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H16Cl3N5
|
||||
| Canonical SMILES |
CN1CCN(CC1)C2=NC=C(C(=N2)N)C3=CC(=CC(=C3Cl)Cl)Cl
|
||||
| InChI |
1S/C15H16Cl3N5/c1-22-2-4-23(5-3-22)15-20-8-11(14(19)21-15)10-6-9(16)7-12(17)13(10)18/h6-8H,2-5H2,1H3,(H2,19,20,21)
|
||||
| InChIKey |
PDOCBJADCWMDGL-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Voltage-dependent L-type calcium channel alpha-1D subunit | Target Info | Inhibitor | [2] | |
| Voltage-gated sodium channel subunit alpha Nav1.3 | Target Info | Inhibitor | [3] | ||
| Sodium channel | Target Info | Inhibitor | [4] | ||
| Sodium channel protein type 4 subunit alpha | Target Info | Inhibitor | [5] | ||
| Sodium channel protein type 5 subunit alpha | Target Info | Inhibitor | [4] | ||
| Voltage-gated sodium channel subunit alpha Nav1.7 | Target Info | Inhibitor | [5] | ||
| Voltage-gated sodium channel subunit alpha Nav1.8 | Target Info | Inhibitor | [5] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Cardiac muscle contraction | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Vascular smooth muscle contraction | |||||
| Circadian entrainment | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Cholinergic synapse | |||||
| Serotonergic synapse | |||||
| GABAergic synapse | |||||
| Dopaminergic synapse | |||||
| Insulin secretion | |||||
| GnRH signaling pathway | |||||
| Oxytocin signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Carbohydrate digestion and absorption | |||||
| Alzheimer's disease | |||||
| Amphetamine addiction | |||||
| Hypertrophic cardiomyopathy (HCM) | |||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||||
| Dilated cardiomyopathyhsa04728:Dopaminergic synapsehsa04261:Adrenergic signaling in cardiomyocytes | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | |||||
| 5HT2 type receptor mediated signaling pathway | |||||
| Beta1 adrenergic receptor signaling pathway | |||||
| Beta2 adrenergic receptor signaling pathway | |||||
| Oxytocin receptor mediated signaling pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenaline,noradrenaline inhibits insulin secretion | ||||
| NCAM1 interactions | |||||
| Regulation of insulin secretionR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and Ankyrins | |||||
| WikiPathways | Calcium Regulation in the Cardiac Cell | ||||
| Arrhythmogenic Right Ventricular Cardiomyopathy | |||||
| Alzheimers Disease | |||||
| NCAM signaling for neurite out-growth | |||||
| Integration of energy metabolismWP706:SIDS Susceptibility Pathways | |||||
| Cardiac Progenitor Differentiation | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003904) | ||||
| REF 2 | Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995). | ||||
| REF 3 | J Med Chem. 2002 Aug 15;45(17):3755-64.Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. | ||||
| REF 4 | J Med Chem. 2001 Jan 18;44(2):115-37.Medicinal chemistry of neuronal voltage-gated sodium channel blockers. | ||||
| REF 5 | J Med Chem. 2009 May 14;52(9):2694-707.Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.